Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses: 2021-2024

Historic Accumulated Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $32.4 million.

  • Kiniksa Pharmaceuticals International's Accumulated Expenses fell 23.37% to $30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year decrease of 23.37%. This contributed to the annual value of $32.4 million for FY2024, which is 16.69% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Accumulated Expenses stood at $32.4 million, which was up 16.69% from $27.7 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Accumulated Expenses ranged from a high of $38.0 million in FY2021 and a low of $27.7 million during FY2023.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Accumulated Expenses averaged around $30.1 million, with its median value being $30.1 million (2022).
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Accumulated Expenses dropped by 20.82% in 2022 and then rose by 16.69% in 2024.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Accumulated Expenses (Yearly) stood at $38.0 million in 2021, then decreased by 20.82% to $30.1 million in 2022, then declined by 7.92% to $27.7 million in 2023, then climbed by 16.69% to $32.4 million in 2024.